A leading infectious disease expert and one of the nation’s foremost COVID-19 researchers has voiced deep concerns about the ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

The S&P 500 added 0.9% on Monday, June 16, as investors absorbed the possibility of cooling geopolitical tensions and looked ...

GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to ...

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...

According to the Alzheimer’s Association, today in America, 7 million people are living with the condition. It is believed ...

( The Hill) — The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include individuals 18-59 years of age who are at increased risk for severe illness ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include individuals 18-59 years of age who are at increased risk for severe illness from ...

The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the ...

The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s ...

The mRNA-based RSV shot, mRESVIA, secured U.S. approval on Thursday for use in at-risk adults aged 18 to 59 years, but needs ...

The halt was triggered by an “imbalance,” the FDA said, in cases of severe lower respiratory tract infections (LRTIs) in children in a phase 1 trial of two Moderna RSV vaccines. One of the ...